The outcome of treatment in differentiated thyroid cancer according to recommendations in current Dutch and American guidelines
Authors' conclusion
Low-risk patients were treated too aggressively when following NL-15 recommendations, where the less aggressive ATA-15 approach seemed more adequate. Treatment of intermediate risk DTC patients varies greatly, with a relative higher rate of undertreatment according to the recommendations of the ATA-15, advocating further refining of the risk classification in this patient group.
Study context
- Population
- Patients with cT1-T3aN0–1aM0 differentiated thyroid cancer (DTC) treated at the University Medical Center Groningen, 2007–2017
- Participants
- 240 patients
- Exposure
- Treatment recommended by NL-15 vs ATA-15 guidelines
- Outcome
- Proportion of potentially adequate, under- and overtreatment of DTC according to each guideline
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Potentially adequate, under- and overtreatment
- NL-15 vs ATA-15: P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | NL-15 | P value |
|---|---|---|
| Overtreatment, congruent low-risk subgroup (n = 60) | 64% | P < 0.001 |
- Undertreatment, incongruent risk subgroup (n = 107)
- P < 0.001
- Undertreatment, incongruent risk subgroup (n = 107): undertreatment most often seen in the incongruent risk group with ATA-15
Treatment, congruent high-risk subgroup (n = 73)
- No treatment differences found
Original publication
The outcome of treatment in differentiated thyroid cancer according to recommendations in current Dutch and American guidelines. Clin Endocrinol (Oxf). Published 16 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →